The 36-month beta value for CRNX is also noteworthy at 0.28. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CRNX is 86.66M, and at present, short sellers hold a 11.78% of that float. The average trading volume of CRNX on June 19, 2025 was 937.06K shares.
CRNX) stock’s latest price update
The stock price of Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) has dropped by -1.13 compared to previous close of 30.85. Despite this, the company has seen a fall of -5.66% in its stock price over the last five trading days. globenewswire.com reported 2025-06-16 that SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that it will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00 AM to 12:00 PM ET. The event will provide an update including data on Crinetics’ early-stage pipeline assets, next steps, and portfolio strategy to drive long-term value.
CRNX’s Market Performance
CRNX’s stock has fallen by -5.66% in the past week, with a monthly drop of -1.45% and a quarterly drop of -12.03%. The volatility ratio for the week is 0.32% while the volatility levels for the last 30 days are 2.03% for Crinetics Pharmaceuticals Inc The simple moving average for the last 20 days is -2.54% for CRNX’s stock, with a simple moving average of -29.18% for the last 200 days.
Analysts’ Opinion of CRNX
Many brokerage firms have already submitted their reports for CRNX stocks, with Stifel repeating the rating for CRNX by listing it as a “Buy.” The predicted price for CRNX in the upcoming period, according to Stifel is $60 based on the research report published on March 25, 2025 of the current year 2025.
CRNX Trading at -2.27% from the 50-Day Moving Average
After a stumble in the market that brought CRNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.22% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRNX starting from Betz Stephen F., who sale 97,483 shares at the price of $32.23 back on Jun 12 ’25. After this action, Betz Stephen F. now owns 99,713 shares of Crinetics Pharmaceuticals Inc, valued at $3,141,877 using the latest closing price.
STEPHEN BETZ, the Officer of Crinetics Pharmaceuticals Inc, proposed sale 97,483 shares at $32.33 during a trade that took place back on Jun 12 ’25, which means that STEPHEN BETZ is holding shares at $3,151,625 based on the most recent closing price.
Stock Fundamentals for CRNX
Current profitability levels for the company are sitting at:
- -495.7 for the present operating margin
- 0.01 for the gross margin
The net margin for Crinetics Pharmaceuticals Inc stands at -431.91. The total capital return value is set at -0.29. Equity return is now at value -30.84, with -28.06 for asset returns.
Based on Crinetics Pharmaceuticals Inc (CRNX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -5.15.
Currently, EBITDA for the company is -338.85 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 3701.96. The liquidity ratio also appears to be rather interesting for investors as it stands at 22.53.
Conclusion
In summary, Crinetics Pharmaceuticals Inc (CRNX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
